{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T11:00:59Z","timestamp":1778670059114,"version":"3.51.4"},"reference-count":33,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2008,11,10]],"date-time":"2008-11-10T00:00:00Z","timestamp":1226275200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2009,1]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The aim of this study was to describe the relationship between age and the time to treatment discontinuation in the absence of virological failure as well as the development of specific laboratory abnormalities, in patients starting highly active antiretroviral therapy (HAART) for the first time.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Analyses included 8708 antiretroviral\u2010na\u00efve patients from the UK Collaborative HIV Cohort (CHIC) study who started HAART from 1998 onwards. We considered time to the first discontinuation of any drug in the initial HAART regimen for reasons other than virological failure; the association between this and age at the start of HAART was determined using proportional hazards regression after adjustment for potential confounders. The incidence of specific laboratory abnormalities in the first year after starting HAART was compared in those of different ages using multiple logistic regression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 2650 patients discontinued at least one drug in their HAART regimen in the first year for reasons other than virological failure; after controlling for confounders, those aged &lt; 30 years at the time of starting HAART were more likely to discontinue than those aged 30\u201339 years [relative hazard (RH) 1.12; 95% confidence interval (CI) 1.01, 1.24] as were those aged  50 years (RH 1.14; 95% CI 1.00, 1.31). There were strong associations between greater age and raised total cholesterol, decreased haemoglobin and raised triglycerides over the first year, although the latter disappeared after adjustment for pre\u2010HAART levels, suggesting that this finding reflected higher pre\u2010HAART triglyceride levels in older individuals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Continued attempts to improve the tolerability of HAART regimens may help to sustain the good outcomes in all age groups over the longer term.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2008.00654.x","type":"journal-article","created":{"date-parts":[[2008,11,11]],"date-time":"2008-11-11T01:36:01Z","timestamp":1226367361000},"page":"35-43","source":"Crossref","is-referenced-by-count":24,"title":["The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy"],"prefix":"10.1111","volume":"10","author":[{"given":"CA","family":"Sabin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CJ","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Delpech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Bansi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Gilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Schwenk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Leen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Gazzard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Porter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Mackie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Orkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Easterbrook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AN","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the UK Collaborative HIV Cohort (CHIC) Study","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,12,16]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki411"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2003.07.001"},{"key":"e_1_2_6_4_2","first-page":"1463","article-title":"The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group. Response to combination ART","volume":"22","year":"2008","journal-title":"variation by age"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.7.684"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200410210-00007"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2006.00420.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2006.0255"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200003310-00005"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200312010-00008"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200204150-00010"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-2662.2001.00094.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/318154"},{"key":"e_1_2_6_14_2","first-page":"320","article-title":"Interruption and discontinuation of highly active antiretroviral therapy in the Multicenter AIDS Cohort Study","volume":"38","author":"Li X","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_2_6_15_2","first-page":"743","article-title":"Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen","volume":"21","author":"Mocroft A","year":"2005","journal-title":"increased incidence of stopping due to toxicity or patient\/physician choice in patients with hepatitis C coinfection"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2006.00355.x"},{"key":"e_1_2_6_17_2","first-page":"115","article-title":"The creation of a large UK\u2010based multicentre cohort of HIV\u2010infected individuals","volume":"5","author":"The UK Collaborative HIV Cohort Steering Committee.","year":"2004","journal-title":"the UK Collaborative HIV Cohort (UK CHIC) Study"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(96)00077-0"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.332.7556.1489"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2006.22.825"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-200006010-00005"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200203290-00009"},{"key":"e_1_2_6_23_2","first-page":"320","article-title":"Interruption and discontinuation of highly active antiretroviral therapy in the Multicenter AIDS Cohort Study","volume":"38","author":"Li X","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1086\/518619"},{"key":"e_1_2_6_25_2","first-page":"1322","article-title":"Prevalence of adverse events associated with potent antiretroviral treatment","volume":"358","author":"Fellay J","year":"2001","journal-title":"Swiss HIV Cohort Study"},{"key":"e_1_2_6_26_2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/135965350501000105","article-title":"Body fat changes among antiretroviral\u2010na\u00efve patients on PI\u2010 and NNRTI\u2010based HAART in the Swiss HIV Cohort Study","volume":"10","author":"Young U","year":"2005","journal-title":"Antiviral Ther"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200108150-00002"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(01)00443-7"},{"key":"e_1_2_6_29_2","unstructured":"University of Liverpool. HIV Drug Interactions Website. Available from:http:\/\/www.hiv\u2010druginteractions.org"},{"key":"e_1_2_6_30_2","first-page":"1481","article-title":"Adherence to highly active antiretroviral therapies (HAART) in HIV\u2010infected patients","volume":"54","author":"Spire B","year":"2002","journal-title":"from a predictive to a dynamic approach"},{"key":"e_1_2_6_31_2","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1177\/135965350501000511","article-title":"Lipid profiles for antiretroviral\u2010na\u00efve patients starting PI\u2010 and NNRTI\u2010based therapy in the Swiss HIV Cohort Study","volume":"10","author":"Young J","year":"2005","journal-title":"Antivir Ther"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2008.00636.x"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2004.00246.x"},{"key":"e_1_2_6_34_2","unstructured":"Health Protection Agency. Numbers of persons accessing HIV\u2010related care. Survey of Prevalent HIV Infections Diagnosed (SOPHID). National data tables. Available from:http:\/\/www.hpa.org.uk\/web\/HPAwebFile\/HPAweb\u2010C\/1203064764730"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2008.00654.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2008.00654.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T19:45:11Z","timestamp":1696880711000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2008.00654.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,16]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["10.1111\/j.1468-1293.2008.00654.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2008.00654.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,16]]}}}